{"entity":{"id":"neuregen-therapeutics","kind":"company","name":"Neuregen Therapeutics","aka":["Neuregen Therapeutics Co., Ltd.","纽伦捷生物医药科技（武汉）有限公司"],"tldr":"Neuregen Therapeutics is testing an injection for high-grade brain tumours that combines a cancer-killing virus, an immune booster and a technique meant to turn leftover tumour cells into cells that no longer divide.","summary":"Neuregen Therapeutics Co., Ltd. (纽伦捷生物), whose Wuhan entity was founded in December 2021 according to the company and whose website gives a Shanghai address, develops therapies based on in vivo cell reprogramming (in situ transdifferentiation), with a pipeline focused on nervous system tumours and blinding eye disease. NRG-103 injection combines a recombinant oncolytic virus, an immune-enhancing cytokine and in situ transdifferentiation of residual tumour cells; the company reports FDA IND clearance and orphan drug designation, and implied IND approval from China's CDE in January 2026. A phase 1 trial is enrolling patients with recurrent or progressive high-grade glioma (NCT07710690). The company announced a Series A in May 2026, led by a Wuhan Optics Valley fund. Its first registered cancer trial, NCT07710690, was posted on ClinicalTrials.gov in July 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.nrg-therapeutics.com/"},{"label":"Company profile and milestones","url":"https://www.nrg-therapeutics.com/company_profile.html"},{"label":"ClinicalTrials.gov: phase 1 trial of NRG-103 in high-grade glioma (NCT07710690)","url":"https://clinicaltrials.gov/study/NCT07710690"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus","cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company profile, milestones and news (Chinese) read on 29 October 2026. The FDA designations are the company's own statements and were not checked against FDA records."],"hq":"Wuhan","country":"CN","companyType":"biotech","website":"https://www.nrg-therapeutics.com/","founded":2021,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"source":"https://www.nrg-therapeutics.com/news.html","note":"Led by Wuhan Optics Valley Science and Innovation Industry Investment Fund; amount not stated. The company says 2025 financing totalled nearly RMB 100 million"}]},"route":"/companies/neuregen-therapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}]}}